Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Ralpha with a KD of 20.7 pM when binding to human IL-4Ralpha epitopes. Rademikibart does not bind to IL-4Ralpha from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research[1].
Molecular Weight:
(145.36 kDa)
Purity:
99.13
CAS Number:
[2648260-80-2]
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
